Bio-pharmaceutical products are bio-active preparations made from microorganisms, parasites, animal toxins, and biological tissues as starting materials, prepared by biological processes or by separation and purification techniques, and controlled by biotechnology and analytical techniques to control the quality of intermediate products and finished products. Such as epidemic (bacteria) seedlings, toxins, toxins, immune serum, blood products, immunoglobulins, antigens, allergens, cytokines and so on.
In the current Customs Export Tariff Code, there is no unified and definitive biomedical tax code. Biopharmaceuticals such as genetic engineering vaccines, monoclonal antibodies, interferons, and blood products are usually imported and exported through tax code number 3002. Therefore, the domestic statistics of biomedical data is difficult to completely reflect the actual situation of China's biopharmaceutical import and export. However, there is no doubt that the import and export of biopharmaceuticals in China will show strong growth momentum.
In 2009, China’s biopharmaceuticals import and export amounted to US$887 million, an increase of 44.35% over the same period of the previous year, of which exports increased by 53.16% year-on-year, and vaccine exports increased by 19.71% year-on-year.
China's biopharmaceuticals import and export are facing a good opportunity for development. With the strong support of the government, China's biopharmaceutical industry has made great progress, and has become more and more closely linked with the international biopharmaceutical industry, maintaining a substantial increase in imports of biopharmaceuticals. At the same time, exports of some biopharmaceutical products are also steadily increasing.
In 2009, China's biopharmaceutical imports and exports amounted to 887 million U.S. dollars, an increase of 44.35% year-on-year. Among them, the export value was 87.175 million US dollars, an increase of 53.16%; the amount of imports was 800 million US dollars, an increase of 43.35%, both import and export showed a trend of substantial growth, full of stamina. At present, China's biopharmaceutical companies have grown to more than 500 and biopharmaceutical industry sales revenue exceeds 40 billion yuan, but it is lower than the proportion of the global biopharmaceutical industry in the pharmaceutical industry, indicating that China's biopharmaceutical industry still has very large room for development. It can be predicted that China's biopharmaceutical imports and exports will continue to maintain rapid growth in 2010.
Export
Asia is the main market and there is a major breakthrough in vaccines
ã€Industry】 In 2009, there were 135 enterprises engaged in the export of biopharmaceutical products in China, 20 companies with export value over US$1 million, Chengdu Institute of Biological Products, Aide Detection Technology Co., Ltd., and Shanghai Lai Shi Blood Products. Co., Ltd., Hualan Biological Engineering Co., Ltd., Sichuan Kelun Bio-Pharmaceutical Co., Ltd., Aibo Bio-Pharmaceuticals (Hangzhou) Co., Ltd., Lanzhou Bio-Technology Development Co., Ltd., Shanghai Kehua Bio-Engineering Co., Ltd., Liaoning Chengda Bio The shares of Sichuan Co., Ltd. and Sichuan Sunda Pharmaceutical Co., Ltd. rank among the top 10 in China's bio-pharmaceutical exports, accounting for 59.66%.
[Market] In 2009, China's bio-pharmaceuticals were exported to 126 countries and regions. Asia is the major export market, accounting for 59.57% of the total. In 2009, China’s top ten export trading partners for biopharmaceuticals were India, the United States, Hong Kong, Canada, Egypt, Ethiopia, Vietnam, Indonesia, Thailand and Pakistan, which accounted for 77.99% of the total, of which only the Indian market accounted for the largest proportion. 34.66%.
[Variety] In 2009, China's export of human vaccines was 19.1576 million US dollars, a year-on-year increase of 19.71%. It was exported to 35 countries and regions. There are no export records for Oceania and North America. The main export markets are India, Pakistan, and South Korea. Malawi and Thailand accounted for 84.63% of the total, of which only India accounted for 67.39%.
A total of 20 companies in China are exporting human vaccines, Chengdu Institute of Biological Products, Liaoning Chengda Biological Co., Ltd., Changchun Institute of Biological Products, Shenzhen Import and Export Development Co., Ltd., Changchun Changsheng Biotechnology Co., Ltd. Equal ranking ranked the top five in terms of human vaccine exports in 2009, accounting for 87.19% of the total, of which only the Chengdu Institute of Biological Products accounted for as much as 45.92%.
Since the beginning of the new century, with the rapid spread of SARS, H5N1, H1N1 and other viruses, various types of outbreaks have spread globally, making the vaccine market demand increase substantially. It is predicted that the global vaccine market sales will increase at a rate of 18%. By 2011, the global vaccine market sales will increase to 30 billion US dollars.
As China's vaccines are inexpensive and affordable, they are very popular in Asia and Africa and maintain a rapid growth momentum. After many years of hard work, Chengdu Institute of Biological Products successfully passed the review of Indian drug regulatory authorities. Its JE vaccine with independent intellectual property rights entered the Indian government procurement system, which indicates that the level of China's biopharmaceutical industry has been greatly improved, but currently Except Chengdu Institute of Biological Products, there are no other domestic enterprises that have entered the scope of government procurement abroad.
The export value of “Human Blood, Medical Animal Blood Products, Other Toxins, and Cultured Microorganisms†with tariff number 30029090 was 11.3466 million US dollars, an increase of 21.09% over the same period of last year. The total exports were to 31 countries and regions, and the major export markets were Hong Kong, India, China, and China. The United States, Japan and the United Kingdom accounted for 89.23% of the total, of which China's Hong Kong accounted for 41.74%. There are 55 companies in the country that export such commodities, including Lanzhou Biotechnology Development Co., Ltd., Sichuan Kelun Bio-Pharmaceutical Co., Ltd., Novozymes (Shenyang) Bio-Processing Co., Ltd., Beijing Boermai Biotechnology Co., Ltd. and Beijing Deere. Takin Biotech Co., Ltd. ranked among the top 5 exporters of this category, accounting for 84.65% of the total. Some interferons have also been reported to export through tax code number 30029090. Interferon is a type of secretory protein that has broad-spectrum antiviral, antitumor, and immunoregulatory properties and is commonly used to treat chronic hepatitis B, C, and D hepatitis.
The export volume of “Antiserum and other blood components and modified immunological products†with tax code number 30021000 was USD 46.956 million, an increase of 100.35% over the same period of last year. The total exports were to 115 countries and regions. The main export markets were India, the United States, Canada, and Ethiopia. In Thailand, the proportion is as high as 65.36%, of which India accounts for 31.47%. There are 67 companies in the country that are exporting such commodities, including Aide Detection Technology Co., Ltd., Shanghai Laise Blood Products Co., Ltd., and Hualan Biological Engineering. The joint stock company, Aibo Bio-pharmaceuticals (Hangzhou) Co., Ltd. and Shanghai Kehua Bio-engineering Co., Ltd. ranked among the top 5 exporters of such commodities in 2009, accounting for 62.17% of the total.
import
Europe and the United States account for the big head and the trade deficit is still large
[Enterprises] According to relevant data, in 2009, there were 406 companies operating biopharmaceutical imports nationwide, and 63 companies with imports exceeding US$1 million, Shanghai GlaxoSmithKline Biological Products Co., Ltd. and Roche Diagnostics (Shanghai) Co., Ltd., Guangdong Nanfang Pharmaceutical Foreign Trade Co., Ltd., Customs code 4403040516, China Animal Husbandry & Industry (Group) Corporation, Huadong Pharmaceutical Co., Ltd., Yongyu (Shanghai) Pharmaceutical Logistics Operation Co., Ltd., Baxter Medical Products Trading ( Shanghai) Co., Ltd., a company with a customs code of 1111960397, and Tianjin Waige Group Chemicals and Pharmaceuticals Co., Ltd. ranked among the top 10 biomedical imports in China, accounting for 63.74% of the total.
[Market] In 2009, China imported biopharmaceuticals from 43 countries and regions. Europe and North America are the major import markets, accounting for 96.55% of the two markets. In 2009, the top ten trade partners of China's biopharmaceutical imports were the United States, Germany, Austria, France, Belgium, Switzerland, Ireland, the Netherlands, Spain, and Italy, with a proportion of 93.56%, of which only the U.S. and German markets accounted for the highest proportion. 43.91%, the monopoly market is very obvious.
ã€Variety】 Imports of human vaccines amounted to US$196 million, an increase of 6.41% year-on-year. A total of 11 companies in the country operated such goods. Shanghai GlaxoSmithKline Biological Products Co., Ltd. topped the list of human vaccine imports, which accounted for the largest proportion. 61.42%, its imports are mainly GSK's recombinant (yeast) hepatitis B vaccine liquid products, and currently there are few other foreign hepatitis B vaccine products. Recombinant (yeast) hepatitis B vaccine is currently the backbone of domestic and international applications, mainly represented by Merck and GlaxoSmithKline.
The import value of taxation number 30029090 “Human blood, medical animal blood products, other toxins, and cultured microorganisms†was 47.984 million US dollars, an increase of 50.76% year-on-year. A total of 175 enterprises throughout the country operated such goods, including Danisco (China) Co., Ltd. Shanghai Guoyao Waigaoqiao Pharmaceutical Co., Ltd., Hainan Huaxuan Pharmaceutical Co., Ltd., and companies with customs codes 4601161096 and Beijing Tobida West Pharmaceutical Co., Ltd. ranked among the top five in terms of import value of such commodities, accounting for 84.65% of the total.
[Rethinking] At present, China's biopharmaceutical exports are mainly restricted by technical barriers such as foreign registration. Due to the stringent requirements of foreign countries for the quality standards of biopharmaceuticals, combined with the lack of international market development capabilities of enterprises, insufficient funds and energy are invested to cause biopharmaceuticals in China. The import and export trade deficit is too large.
To change this situation, it is necessary to further optimize the structure of export commodities, strengthen cooperation with countries and regions with developed biomedical industries, actively introduce technology and talents, and strengthen research on biomedical policies and regulations in developed countries and regions. Through the registration of the World Health Organization and efforts to obtain procurement orders from the United Nations, it will certainly open up the export space for biopharmaceuticals in the international market.
In the current Customs Export Tariff Code, there is no unified and definitive biomedical tax code. Biopharmaceuticals such as genetic engineering vaccines, monoclonal antibodies, interferons, and blood products are usually imported and exported through tax code number 3002. Therefore, the domestic statistics of biomedical data is difficult to completely reflect the actual situation of China's biopharmaceutical import and export. However, there is no doubt that the import and export of biopharmaceuticals in China will show strong growth momentum.
In 2009, China’s biopharmaceuticals import and export amounted to US$887 million, an increase of 44.35% over the same period of the previous year, of which exports increased by 53.16% year-on-year, and vaccine exports increased by 19.71% year-on-year.
China's biopharmaceuticals import and export are facing a good opportunity for development. With the strong support of the government, China's biopharmaceutical industry has made great progress, and has become more and more closely linked with the international biopharmaceutical industry, maintaining a substantial increase in imports of biopharmaceuticals. At the same time, exports of some biopharmaceutical products are also steadily increasing.
In 2009, China's biopharmaceutical imports and exports amounted to 887 million U.S. dollars, an increase of 44.35% year-on-year. Among them, the export value was 87.175 million US dollars, an increase of 53.16%; the amount of imports was 800 million US dollars, an increase of 43.35%, both import and export showed a trend of substantial growth, full of stamina. At present, China's biopharmaceutical companies have grown to more than 500 and biopharmaceutical industry sales revenue exceeds 40 billion yuan, but it is lower than the proportion of the global biopharmaceutical industry in the pharmaceutical industry, indicating that China's biopharmaceutical industry still has very large room for development. It can be predicted that China's biopharmaceutical imports and exports will continue to maintain rapid growth in 2010.
Export
Asia is the main market and there is a major breakthrough in vaccines
ã€Industry】 In 2009, there were 135 enterprises engaged in the export of biopharmaceutical products in China, 20 companies with export value over US$1 million, Chengdu Institute of Biological Products, Aide Detection Technology Co., Ltd., and Shanghai Lai Shi Blood Products. Co., Ltd., Hualan Biological Engineering Co., Ltd., Sichuan Kelun Bio-Pharmaceutical Co., Ltd., Aibo Bio-Pharmaceuticals (Hangzhou) Co., Ltd., Lanzhou Bio-Technology Development Co., Ltd., Shanghai Kehua Bio-Engineering Co., Ltd., Liaoning Chengda Bio The shares of Sichuan Co., Ltd. and Sichuan Sunda Pharmaceutical Co., Ltd. rank among the top 10 in China's bio-pharmaceutical exports, accounting for 59.66%.
[Market] In 2009, China's bio-pharmaceuticals were exported to 126 countries and regions. Asia is the major export market, accounting for 59.57% of the total. In 2009, China’s top ten export trading partners for biopharmaceuticals were India, the United States, Hong Kong, Canada, Egypt, Ethiopia, Vietnam, Indonesia, Thailand and Pakistan, which accounted for 77.99% of the total, of which only the Indian market accounted for the largest proportion. 34.66%.
[Variety] In 2009, China's export of human vaccines was 19.1576 million US dollars, a year-on-year increase of 19.71%. It was exported to 35 countries and regions. There are no export records for Oceania and North America. The main export markets are India, Pakistan, and South Korea. Malawi and Thailand accounted for 84.63% of the total, of which only India accounted for 67.39%.
A total of 20 companies in China are exporting human vaccines, Chengdu Institute of Biological Products, Liaoning Chengda Biological Co., Ltd., Changchun Institute of Biological Products, Shenzhen Import and Export Development Co., Ltd., Changchun Changsheng Biotechnology Co., Ltd. Equal ranking ranked the top five in terms of human vaccine exports in 2009, accounting for 87.19% of the total, of which only the Chengdu Institute of Biological Products accounted for as much as 45.92%.
Since the beginning of the new century, with the rapid spread of SARS, H5N1, H1N1 and other viruses, various types of outbreaks have spread globally, making the vaccine market demand increase substantially. It is predicted that the global vaccine market sales will increase at a rate of 18%. By 2011, the global vaccine market sales will increase to 30 billion US dollars.
As China's vaccines are inexpensive and affordable, they are very popular in Asia and Africa and maintain a rapid growth momentum. After many years of hard work, Chengdu Institute of Biological Products successfully passed the review of Indian drug regulatory authorities. Its JE vaccine with independent intellectual property rights entered the Indian government procurement system, which indicates that the level of China's biopharmaceutical industry has been greatly improved, but currently Except Chengdu Institute of Biological Products, there are no other domestic enterprises that have entered the scope of government procurement abroad.
The export value of “Human Blood, Medical Animal Blood Products, Other Toxins, and Cultured Microorganisms†with tariff number 30029090 was 11.3466 million US dollars, an increase of 21.09% over the same period of last year. The total exports were to 31 countries and regions, and the major export markets were Hong Kong, India, China, and China. The United States, Japan and the United Kingdom accounted for 89.23% of the total, of which China's Hong Kong accounted for 41.74%. There are 55 companies in the country that export such commodities, including Lanzhou Biotechnology Development Co., Ltd., Sichuan Kelun Bio-Pharmaceutical Co., Ltd., Novozymes (Shenyang) Bio-Processing Co., Ltd., Beijing Boermai Biotechnology Co., Ltd. and Beijing Deere. Takin Biotech Co., Ltd. ranked among the top 5 exporters of this category, accounting for 84.65% of the total. Some interferons have also been reported to export through tax code number 30029090. Interferon is a type of secretory protein that has broad-spectrum antiviral, antitumor, and immunoregulatory properties and is commonly used to treat chronic hepatitis B, C, and D hepatitis.
The export volume of “Antiserum and other blood components and modified immunological products†with tax code number 30021000 was USD 46.956 million, an increase of 100.35% over the same period of last year. The total exports were to 115 countries and regions. The main export markets were India, the United States, Canada, and Ethiopia. In Thailand, the proportion is as high as 65.36%, of which India accounts for 31.47%. There are 67 companies in the country that are exporting such commodities, including Aide Detection Technology Co., Ltd., Shanghai Laise Blood Products Co., Ltd., and Hualan Biological Engineering. The joint stock company, Aibo Bio-pharmaceuticals (Hangzhou) Co., Ltd. and Shanghai Kehua Bio-engineering Co., Ltd. ranked among the top 5 exporters of such commodities in 2009, accounting for 62.17% of the total.
import
Europe and the United States account for the big head and the trade deficit is still large
[Enterprises] According to relevant data, in 2009, there were 406 companies operating biopharmaceutical imports nationwide, and 63 companies with imports exceeding US$1 million, Shanghai GlaxoSmithKline Biological Products Co., Ltd. and Roche Diagnostics (Shanghai) Co., Ltd., Guangdong Nanfang Pharmaceutical Foreign Trade Co., Ltd., Customs code 4403040516, China Animal Husbandry & Industry (Group) Corporation, Huadong Pharmaceutical Co., Ltd., Yongyu (Shanghai) Pharmaceutical Logistics Operation Co., Ltd., Baxter Medical Products Trading ( Shanghai) Co., Ltd., a company with a customs code of 1111960397, and Tianjin Waige Group Chemicals and Pharmaceuticals Co., Ltd. ranked among the top 10 biomedical imports in China, accounting for 63.74% of the total.
[Market] In 2009, China imported biopharmaceuticals from 43 countries and regions. Europe and North America are the major import markets, accounting for 96.55% of the two markets. In 2009, the top ten trade partners of China's biopharmaceutical imports were the United States, Germany, Austria, France, Belgium, Switzerland, Ireland, the Netherlands, Spain, and Italy, with a proportion of 93.56%, of which only the U.S. and German markets accounted for the highest proportion. 43.91%, the monopoly market is very obvious.
ã€Variety】 Imports of human vaccines amounted to US$196 million, an increase of 6.41% year-on-year. A total of 11 companies in the country operated such goods. Shanghai GlaxoSmithKline Biological Products Co., Ltd. topped the list of human vaccine imports, which accounted for the largest proportion. 61.42%, its imports are mainly GSK's recombinant (yeast) hepatitis B vaccine liquid products, and currently there are few other foreign hepatitis B vaccine products. Recombinant (yeast) hepatitis B vaccine is currently the backbone of domestic and international applications, mainly represented by Merck and GlaxoSmithKline.
The import value of taxation number 30029090 “Human blood, medical animal blood products, other toxins, and cultured microorganisms†was 47.984 million US dollars, an increase of 50.76% year-on-year. A total of 175 enterprises throughout the country operated such goods, including Danisco (China) Co., Ltd. Shanghai Guoyao Waigaoqiao Pharmaceutical Co., Ltd., Hainan Huaxuan Pharmaceutical Co., Ltd., and companies with customs codes 4601161096 and Beijing Tobida West Pharmaceutical Co., Ltd. ranked among the top five in terms of import value of such commodities, accounting for 84.65% of the total.
[Rethinking] At present, China's biopharmaceutical exports are mainly restricted by technical barriers such as foreign registration. Due to the stringent requirements of foreign countries for the quality standards of biopharmaceuticals, combined with the lack of international market development capabilities of enterprises, insufficient funds and energy are invested to cause biopharmaceuticals in China. The import and export trade deficit is too large.
To change this situation, it is necessary to further optimize the structure of export commodities, strengthen cooperation with countries and regions with developed biomedical industries, actively introduce technology and talents, and strengthen research on biomedical policies and regulations in developed countries and regions. Through the registration of the World Health Organization and efforts to obtain procurement orders from the United Nations, it will certainly open up the export space for biopharmaceuticals in the international market.
SICHUAN UNIWELL BIOTECHNOLOGY CO.,LTD. , https://www.uniwellbio.com